Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
BCG failure
CIS
HIVEC
NMIBC
bladder cancer
progression
recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Feb 2023
24 Feb 2023
Historique:
received:
29
01
2023
revised:
22
02
2023
accepted:
23
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated. This study aims to investigate the efficacy of Hyperthermic IntraVesical Chemotherapy (HIVEC) depending on the presence or absence of CIS. This retrospective, multicenter study was conducted between 2016 and 2021. Patients with non-muscle-invasive bladder cancer (NMIBC) with BCG failure received 6-8 adjuvant instillations of HIVEC. The co-primary endpoints were recurrence-free survival (RFS) and progression-free survival (PFS). A total of 116 consecutive patients met our inclusion criteria of whom 36 had concomitant CIS. The 2-year RFS rate was 19.9% and 43.7% in patients with and without CIS, respectively (
Identifiants
pubmed: 36900247
pii: cancers15051455
doi: 10.3390/cancers15051455
pmc: PMC10001134
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Eur Urol. 2019 Jan;75(1):63-71
pubmed: 30274699
World J Urol. 2009 Feb;27(1):21-5
pubmed: 19066905
Scand J Urol Nephrol Suppl. 1994;157:147-51
pubmed: 7939446
Eur Urol. 2004 Mar;45(3):292-6
pubmed: 15036673
Virchows Arch. 2015 May;466(5):589-94
pubmed: 25697540
Curr Opin Urol. 2021 May 1;31(3):178-187
pubmed: 33742981
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Bladder Cancer. 2018 Oct 29;4(4):365-376
pubmed: 30417047
Eur Urol. 2015 Mar;67(3):402-22
pubmed: 25560797
Urol Oncol. 2022 Feb;40(2):62.e13-62.e20
pubmed: 34470725
Eur Urol. 2011 Jul;60(1):81-93
pubmed: 21531502
Br J Clin Pharmacol. 2001 Sep;52(3):273-8
pubmed: 11560559
Eur Urol. 2022 Aug 20;:
pubmed: 35999119
BJU Int. 2011 Mar;107(6):912-8
pubmed: 21029314
Int J Hyperthermia. 2020;37(1):854-860
pubmed: 32664768
Int J Hyperthermia. 2009 Feb;25(1):3-20
pubmed: 19219695
Oncoimmunology. 2021 May 3;10(1):1912885
pubmed: 33996264
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Lancet Oncol. 2021 Jan;22(1):107-117
pubmed: 33253641
Eur Urol. 2022 Jan;81(1):75-94
pubmed: 34511303
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Int J Hyperthermia. 2021;38(1):1633-1638
pubmed: 34775896
Lancet Oncol. 2021 Jul;22(7):919-930
pubmed: 34051177
BMC Cancer. 2018 Dec 6;18(1):1224
pubmed: 30522445
Bladder Cancer. 2018 Oct 29;4(4):395-401
pubmed: 30417050
Eur Urol. 2022 Jul;82(1):34-46
pubmed: 34955291
J Urol. 2002 Nov;168(5):1964-70
pubmed: 12394686
Int J Hyperthermia. 1995 Jul-Aug;11(4):459-88
pubmed: 7594802
World J Urol. 2022 Apr;40(4):999-1004
pubmed: 35037963
Eur Urol. 2010 Apr;57(4):595-606
pubmed: 20004052
Eur Urol. 2016 Jun;69(6):1046-52
pubmed: 26803476
Eur Urol Oncol. 2020 Jun;3(3):318-340
pubmed: 32201133
Urol Oncol. 2022 Sep;40(9):409.e1-409.e8
pubmed: 35232680
Cell Stress Chaperones. 1998 Dec;3(4):245-55
pubmed: 9880237
J Urol. 1996 Apr;155(4):1227-32
pubmed: 8632537
Eur Urol Oncol. 2023 Feb;6(1):58-66
pubmed: 36435738